Goldman Sachs Group Inc Humacyte, Inc. Call Options Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding HUMA
# of Institutions
150Shares Held
35.1MCall Options Held
279KPut Options Held
607K-
Black Rock Inc. New York, NY7.14MShares$33.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.06MShares$23.5 Million0.0% of portfolio
-
State Street Corp Boston, MA4.76MShares$22.1 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.04MShares$9.47 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.27MShares$5.88 Million0.0% of portfolio
About Humacyte, Inc.
- Ticker HUMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,007,000
- Market Cap $478M
- Description
- Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...